Longitudinal vasculature changes in branch retinal vein occlusion with projection-resolved optical coherence tomography angiography
To analyze vascular changes in branch retinal vein occlusion (BRVO) using projection-resolved optical coherence tomography angiography (PR-OCTA).
We reviewed 30 consecutive eyes of 30 cases with BRVO retrospectively. PR-OCTA was performed during the acute, intermediate, and remission phases when anti-vascular endothelial growth factor drugs suppress cystic changes. The main outcome measures were vessel density (VD) and retinal thickness changes in the superficial capillary plexus (SCP), intermediate capillary plexus (ICP), and deep capillary plexus (DCP).
The VDs did not change longitudinally in the SCP and DCP during the follow-up period. The VD was significantly (p = 0.0105) greater in the ICP during remission than the acute phase. The full retinal thickness (internal limiting membrane [ILM] to retinal pigment epithelium [RPE]) and inner retinal thickness (ILM to inner plexiform layer [IPL]) decreased significantly (p = 0.0002 and p = 0.0014, respectively) during the follow-up period. When the inner retina was thinner than 117 μm, the VD in the ICP increased significantly (p = 0.045) during the follow-up period. When the inner retinal layer did not become thinner, the VD in the ICP remained unchanged.
PR-OCTA showed the three distinct vascular plexuses in BRVO. The VDs remained unchanged during the follow-up period in the SCP and DCP but increased significantly in the ICP during remission. Inner retinal thinning might cause increases in the VD in the ICP because of projection artifacts and segmentation errors despite using PR-OCTA.
KeywordsProjection-resolved optical coherence tomography angiography Optical coherence tomography angiography Branch retinal vein occlusion Projection artifact
This study was funded in part by the Japan Society for the Promotion of Science (JSPS), Tokyo, Japan (Grant-in-Aid for Scientific Research, no. JP17K16993).
Compliance with ethical standards
Conflict of interest
Author KT has received a research grant from JSPS and Novartis Pharma KK and speaker honoraria from Abbott Medical Optics, Bayer AG, Novartis Pharma KK, and Santen Co. Author MK has received a speaker honoraria from Alcon Japan Ltd., Abbott Medical Optics, Bayer AG, Bausch & Lomb, Ellex, HOYA Surgical Optics, Johnson & Johnson, Kowa Co., Ltd., Nidek Co., Ltd., Novartis Pharma KK, Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc., Santen Co., and Senju Co., Ltd., and received consultant fees from Astellas Pharma Inc., HOYA Surgical Optics, Nidek Co., Ltd., and Senju Co., Ltd.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 8.Hasegawa T, Murakawa S, Maruko I et al (2018) Correlation between reduction in macular vessel density and frequency of intravitreal ranibizumab for macular oedema in eyes with branch retinal vein occlusion. Br J Ophthalmol bjophthalmol 2017 312769Google Scholar
- 9.Yeung L, Wu WC, Chuang LH et al (2018) Novel optical coherence tomography angiography biomarker in branch retinal vein occlusion macular edema. Retina. https://doi.org/10.1097/IAE.0000000000002264